Table 1.

Reported methylation status of the TERT promoter region.

Cell Types	Region Tested	Methylation Status	Reference
SUSM-1, CMV, SiHA, MDA-231/435, Calu 1/3/6, HTB 57/178/182, SW480, HTC 116 (Telomerase +)	From −500 UTSS to +50 first exon (72 CpG sites)	Partial or total methylation	[124]
A549, HTB183 (Telomerase +) NHF, MRC-5/p27 (Telomerase −)	From −500 UTSS to +50 first exon (72 CpG sites)	Unmethylated	[124]
U2OS, telomerase-negative breast carcinoma, VA13 GM847	Promoter region	Partial or total methylation	[127]
CT1485 (Telomerase +) WI38, HA-1 pre-crisis cell strain, JFCF-6T/5K pre-crisis cell strain, IMR90, BJ fibroblast, adrenal carcinoma (Telomerase −)	Promoter region	Unmethylated	[127]
J82, T24, MCF-7, A431, HeLa, Co115, HT29, SW480, H520, SW2, PC-3,	27 CpG sites −441 to −218 relative to UTSS	Partial or total hypermethylation and correlation with TERT mRNA expression and telomerase activity	[17]
Tumour tissues from brain, breast, bladder, colon, kidney, lung, soft tissue
Saos-2, U2-OS (Telomerase −)	27 CpG sites −441 to −218 relative to UTSS	Partial or total hypermethylation	[17]
Normal tissues; skin, brain, bladder, muscle, kidney, heart, placenta, testis, colon		Unmethylation and telomerase negative
HeLa, SW480, Tumour tissues (breast, bladder and cervix) (Telomerase +)	−100 to +100	75 to 100% methylation	[131]
	−165 to −100	0 to 55% methylation
BJ fibroblasts (Telomerase −)	−165 to +100 relative to UTSS	3 to 23% hypomethylation	[131]
Caco-2, HCT116, RKO, SW480, MCF7, MDA-MB-231, MDA-MB-435S, MDA-MB-453, H82, H157, H209, H146, H358, H417, H549, H747, H1299, U1752, DMS53, HL-60, KG-1a, Jurkat, Raji, LCL	−600 bp relative to UTSS	Partial or total methylation and TERT expression	[136]
	−150 to +150 relative to UTSS	Partial or unmethylation
Hepatocarcinoma cell lines HepG2, SNU-182, SNU-398, HCC Tissue (Telomerase +)	−165 to +49 relative to UTSS	10 HCC clones and HepG2 Hypo/unmethylated 12 HCC clones and SNU-182, SNU-398 hypermethylated and reduced TERT	[137]
Normal liver tissue (Telomerase −)	−165 to +49 relative to UTSS	Hypermethylated and reduced TERT	[137]
Malignant pediatric brain tumours	5 CpG sites located UTSS	Hypermethylation TERT expression	[128]
Neuroblastoma	UTSS	Highly methylated	[120]
Hepatocellular carcinoma	−452 to −667 and −974 to −1419 relative to UTSS	Hypermethylation and high TERT expression	[138]
Gastric cancer	25 CpG sites located −555 from UTSS	Hypermethylation and high TERT expression	[134]
Haematopoietic cell lines including Jurkat, THP1, K562, cervical cancer and embryonic kidney cells	−60 to +20 relative to ATG	Hypermethylation and TERT expression	[117]
Normal peripheral blood cell populations (granulocytes, T cells, B cells and monocytes)	−60 to +20 relative to ATG	Unmethylated	[117]
Acute myeloid leukaemia, myelodysplastic syndrome	−520 to −400 relative to ATG	Hypermethylation	[117]
Thyroid cancer	−541 to −578 relative to ATG	Hypermethylation	[139]
Prostate cancer	52 CpG –140 to –572 relative to the UTSS	Hypermethylation	[140]
Melanoma	26 CpG –482 to –667, relative to the ATG	Hypermethylation and positively correlated with the TERT expression	[141]
Melanoma	−945 to −669 bp relative to UTSS	Hypermethylation and positively correlated with the TERT expression	[142]
Pancreatic cancer	Position –575 relative to the UTSS	Hypermethylation	[143]
Colon, blood, breast, prostate, brain, lungs, bladder, ovaries, bone, skin cancers	52 CpG sites −100 to −600 located UTSS	Hypermethylation and upregulated TERT expression	[129]
Bladder cancers	5 CpG sites in –140 to –572 region relative to UTSS	Hypermethylation and higher TERT expression	[132,144]
Primary metastatic medulloblastoma	5 CpG sites localized −600 bp UTSS region	Hypermethylation	[145]
Thyroid Cancer Cell Lines	−662 to +174 relative to UTSS	Hypermethylation of upstream promoter and correlated with TERT expression	[146]